Synlait's back
OPINION: After years of financial turmoil, Canterbury milk processor Synlait is now back in business.
SYNLAIT MILK expects to outperform financial targets on the basis of a favourable product mix.
Current international dairy commodity price differentials are larger than usual, and continue to favour Synlait's milk powder and AMF dominant product mix. The company expects that ongoing demand, particularly from China, will mean that this will be maintained for much of the current season.
While it is still early in the season, recent announcements also make it clear that the current season's milk price is likely to be less than the company was expecting.
Managing director John Penno says Synlait's policy is to pay our contract suppliers a fair market price.
"We now expect the company will benefit from both earnings growth in our value added categories, a favourable product mix, and lower than expected milk prices. This is likely to mean Synlait's earnings for the half and full FY14 will be ahead of forecast".
A full update on Synlait's forecast milk price and financial outlook is expected early in the New Year.
Twenty rural community hubs across New Zealand will receive $5,000 to upgrade their facilities having been selected as the winners of Rabobank's Community Hub Competition.
As the dairy industry prepares to celebrate its top achiever at an awards night this Saturday, attendees are being warned to be aware of protests planned outside the venue – Baypark Arena, Mount Mauganaui.
Beef + Lamb New Zealand (BLNZ) says the release of New Zealand's latest Greenhouse Gas Inventory clearly shows agriculture is playing its part in emissions reductions and there is no need for a price on agricultural emissions.
While opening the first electrode boiler at its Edendale site, Fonterra has announced a $70 million investment in two further new electrode boilers.
Fonterra says its ongoing legal battle with Australian processor Bega Cheese won’t change its divestment plans.
With an amendment to the Medicines Act proposing human medicines could be approved in 30 days if the product has approval from two recognised overseas jurisdictions, there’s a call for a similar approach where possible to be applied to some animal medicines.